Screener
Sutro Biopharma STRO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 9,363 | 10,648 |
| Operating lease right-of-use assets | 9,707 | 10,903 |
| Other non-current assets | 1,088 | 495 |
| Restricted cash | 858 | 858 |
| Total assets | $241,988 | $173,830 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $5,485 | $7,565 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's restricted cash?
- Sutro Biopharma (STRO) reported restricted cash of $858K in Q1 2026.
- How has Sutro Biopharma's restricted cash changed year-over-year?
- Sutro Biopharma's restricted cash decreased by 0.0% year-over-year, from $858K to $858K.
- What is the long-term trend for Sutro Biopharma's restricted cash?
- Over 5 years (2020 to 2025), Sutro Biopharma's restricted cash has grown at a -0.3% compound annual growth rate (CAGR), from $872K to $858K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Sutro Biopharma's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude